TERT and neuroblastoma: In a clinical context, we endorse recent recommendations for integrating TMM assessment into routine protocols, being the minimum information required to classify TMM in neuroblastoma the telomere length (TMM-positive versus TMM-negative), and the presence of APBs or C-circles to distinguish between ALT-positive cases from TMM-positive via telomerase (if possibly confirmed with TERT expression analysis).